# Paclitaxel Plus Carboplatin With or Without Endostar in Patients With Advanced Non-small Cell Lung Cancer

> **NCT00708812** · PHASE2 · COMPLETED · sponsor: **Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd** · enrollment: 126 (actual)

## Conditions studied

- Advanced Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Endostar(Recombinant Human Endostatin Injection)
- **DRUG:** paclitaxel-carboplatin

## Key facts

- **NCT ID:** NCT00708812
- **Lead sponsor:** Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2009-09
- **Final completion:** 2009-12
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2011-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00708812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00708812, "Paclitaxel Plus Carboplatin With or Without Endostar in Patients With Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00708812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*